<p>2025 年 10 月 2 日- 上午 09:16</p>
<p>佛罗里达州多拉尔 --（商业资讯）--NeueHealth, Inc.（“NeueHealth” 或 “公司”）（纽约证券交易所代码：NEUE），一家以价值为驱动的医疗保健公司，今天宣布成功完成其先前宣布的合并，NeueHealth 已被新企业协会（“NEA”）的一个附属公司收购，企业价值约为 14.65 亿美元。</p>
<p>根据合并协议的条款，NeueHealth 普通股的持有者（除了将被转让的股份和某些排除的股份）将获得每股 7.33 美元的现金。包括 NEA 和 12 位现有 NeueHealth 投资者在内的某些股东（这些股东共同持有所有未偿还的 NeueHealth 优先股）已签署了转让协议，根据该协议，这些股东将通过将其 NeueHealth 普通股和/或优先股交换为新发行的私营公司股权继续其投资。NeueHealth 的执行领导团队将继续担任其职务，并已签署转让协议，将其 100% 的股权转让为新发行的私营公司股权。</p>
<p>随着交易的完成，公司普通股于 2025 年 10 月 2 日在纽约证券交易所停止交易。公司计划向美国证券交易委员会（“SEC”）提交相关文件，以暂停其定期报告义务并终止公司活跃注册声明下的 A 类股份的注册。</p>
<p>“自成立以来，NeueHealth 一直致力于使消费者、支付方和提供者的利益保持一致，以创造一个无缝、更加协调的护理体验，” NeueHealth 的总裁兼首席执行官 Mike Mikan 表示。“这笔交易标志着我们公司的一个重要里程碑，因为它使我们能够灵活运用资源，继续实现这一使命，推动我们以价值为驱动、以消费者为中心的护理模式，并在未来实现长期、可持续的增长。”</p>
<p><strong>关于 NeueHealth</strong></p>
<p>NeueHealth 是一家以价值为驱动的医疗保健公司，基于所有健康消费者都有权享受高质量、协调护理的信念。通过独特地使健康消费者、提供者和支付方的利益保持一致，NeueHealth 帮助所有人群在 ACA 市场、医疗保险和医疗补助中获得可及和负担得起的医疗服务。NeueHealth 通过自有诊所和与 3000 多家附属提供者的独特合作关系，为超过 600,000 名健康消费者提供高质量的临床护理。我们还通过一套集中规模化并在本地部署的技术和服务，使独立提供者和医疗集团在基于绩效的安排中蓬勃发展。我们相信，我们以价值为驱动、以消费者为中心的护理模式可以改变医疗体验，并在整个医疗系统中最大化价值。有关更多信息，请访问：www.neuehealth.com。</p>
<p><strong>关于 NEA</strong></p>
<p>新企业协会（New Enterprise Associates, Inc.，简称 NEA）是一家全球风险投资公司，专注于帮助企业家在多个阶段、行业和地区建立变革性企业。NEA 成立于 1977 年，截至 2025 年 6 月 30 日，管理资产超过 280 亿美元，投资于各个生命周期阶段的技术和医疗保健公司，从种子阶段到首次公开募股（IPO）。该公司的投资历史悠久，包括 284 家投资组合公司的 IPO 和超过 500 宗并购交易。有关更多信息，请访问：www.nea.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本公告包含根据 1995 年美国私人证券诉讼改革法案的定义所作出的某些 “前瞻性声明”。本公告中所作的非历史事实的声明，包括关于我们信念和期望的声明，均为前瞻性声明，应当作为此类声明进行评估。前瞻性声明包括有关可能或假定的未来运营结果的信息，包括我们商业计划和战略的描述，以及关于交易的预期时间、完成情况和影响的声明。这些声明通常包含 “预期”、“期待”、“计划”、“相信”、“打算”、“项目”、“预测”、“估计”、“展望”、“确保” 等类似表达。这些前瞻性声明包括关于我们计划、期望和财务指引的任何声明。这些前瞻性声明受到各种风险、不确定性和假设的影响。因此，可能存在或将存在重要因素，导致实际结果或结果与这些声明中所指示的显著不同。可能会实质性影响这些前瞻性声明的因素包括：未能按照预期条款和时间框架完成交易，包括因未能获得所需的股东或监管批准或满足其他成交条件而导致的；可能针对 NEA、公司或其各自的附属公司、董事、管理人员、高管或员工提起的与交易相关的潜在诉讼，以及与此相关的任何结果的影响；由于交易的公告、待决或完成而导致的我们商业关系或运营结果的潜在不利反应或变化；如果交易未能完成，我们的股价可能会显著下跌的风险；在交易待决期间的某些限制可能影响我们追求某些商业机会或战略交易的能力；与交易相关的成本，可能会很高；可能导致合并协议终止的事件、变化或其他情况的发生，包括在需要我们支付终止费用的情况下；我们作为持续经营实体的能力；我们遵守我们的信贷设施或未来进入的任何信贷设施条款的能力；我们及时获得加利福尼亚州医疗保险优势业务出售的剩余收益的能力；我们获得运营业务所需的任何短期或长期债务或股权融资的能力；我们迅速有效地完成剩余个人和家庭计划（“IFP”）和 MA 业务的清算的能力，包括在到期时满足这些业务的负债；由于交易或公司重组及任何导致的裁员而对我们业务造成的潜在干扰；我们准确估计和有效管理与我们业务产品和模式变化相关的成本的能力；从我们的子公司提取受监管资本的延迟或无法；对我们商业模式的接受度不足或缓慢采用；我们保留现有消费者和扩大消费者注册的能力；我们及我们的护理合作伙伴获取和准确评估、编码和报告风险调整因子评分的能力；我们与护理提供者签订合同并安排提供优质护理的能力；我们及时和准确地获取索赔信息的能力；任何疫情或流行病对我们业务和运营结果的影响；我们依赖第三方提供商运营业务的风险；对美国健康保险市场的修改或变化的影响；我们管理业务增长的能力；我们运营、更新或实施我们的技术平台和其他信息技术系统的能力；我们保留关键高管的能力；我们成功追求收购、整合收购的业务以及根据需要迅速有效地剥离业务的能力；严重天气事件、灾难性健康事件、自然或人为灾害以及社会和政治条件或社会动荡的发生；我们防止和控制数据安全事件的能力，以及数据安全事件对我们的成员、患者、员工和财务结果的影响；我们遵守维护有效内部控制要求的能力；我们适应以减轻与我们的 ACO 业务相关的风险的能力，包括任何意想不到的市场或监管发展；以及公司在 Form 10-K、Form 10-Q 和 Form 8-K（包括对这些报告的所有修订）及我们与 SEC 的其他文件中列出的 “风险因素” 标题下列出的其他因素。除法律要求外，我们没有义务在本公告日期后出于任何原因公开更新任何前瞻性声明，以使这些声明与实际结果或我们期望的变化相符。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEwMDE1OTI3OTByMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEwMDE1OTI3OTByMQ"/></p>
<p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20251001592790/en/</p>
<p><strong>投资者联系：</strong></p>
<p>IR@neuehealth.com</p>
<p><strong>媒体联系：</strong></p>
<p>media@neuehealth.com</p>
<p>来源：NeueHealth, Inc.</p>

NEUE

<p>NeueHealth, Inc. 已成功与新企业协会的一个关联公司完成合并，企业价值约为 14.65 亿美元。股东将获得每股 7.33 美元的现金，而某些投资者将把他们的股份转入这家私有公司。此次交易标志着 NeueHealth 的一个重要里程碑，使其能够继续其提供协调护理的使命。合并后，该公司的股票在纽约证券交易所停止交易，并计划暂停向美国证券交易委员会的报告义务</p>

<p>10/02/2025 - 09:16 AM</p>
<div class="lb-trans"><p>2025 年 10 月 2 日- 上午 09:16</p>
</div><p>DORAL, Fla.--(BUSINESS WIRE)--NeueHealth, Inc. (“NeueHealth” or the “Company”) (NYSE: NEUE), the value-driven healthcare company, today announced the successful closing of its previously announced merger under which NeueHealth has been acquired by an affiliate of New Enterprise Associates (“NEA”) at an enterprise value of approximately $1.465 billion.</p>
<div class="lb-trans"><p>佛罗里达州多拉尔 --（商业资讯）--NeueHealth, Inc.（“NeueHealth” 或 “公司”）（纽约证券交易所代码：NEUE），一家以价值为驱动的医疗保健公司，今天宣布成功完成其先前宣布的合并，NeueHealth 已被新企业协会（“NEA”）的一个附属公司收购，企业价值约为 14.65 亿美元。</p>
</div><p>Under the terms of the merger agreement, holders of NeueHealth common stock (other than shares that will be rolled over and certain excluded shares) will receive $7.33 per share in cash. Certain stockholders of NeueHeath, including NEA and 12 existing NeueHealth investors (which collectively hold all of the outstanding shares of NeueHealth preferred stock), have entered into rollover agreements pursuant to which such stockholders will continue their investments by exchanging their shares of NeueHealth common stock and/or preferred stock for newly issued equity interests in the privately held company. NeueHealth’s executive leadership team will continue in their roles and have entered into rollover agreements to roll over 100% of their equity interests for newly issued equity interests in the privately held company.</p>
<div class="lb-trans"><p>根据合并协议的条款，NeueHealth 普通股的持有者（除了将被转让的股份和某些排除的股份）将获得每股 7.33 美元的现金。包括 NEA 和 12 位现有 NeueHealth 投资者在内的某些股东（这些股东共同持有所有未偿还的 NeueHealth 优先股）已签署了转让协议，根据该协议，这些股东将通过将其 NeueHealth 普通股和/或优先股交换为新发行的私营公司股权继续其投资。NeueHealth 的执行领导团队将继续担任其职务，并已签署转让协议，将其 100% 的股权转让为新发行的私营公司股权。</p>
</div><p>With the completion of the transaction, the Company’s common stock ceased trading on the New York Stock Exchange on October 2, 2025. The Company intends to make the applicable filings with the U.S. Securities and Exchange Commission (the “SEC”) to suspend its periodic reporting obligations and to terminate the registration of the Class A Shares underlying the Company’s active registration statements.</p>
<div class="lb-trans"><p>随着交易的完成，公司普通股于 2025 年 10 月 2 日在纽约证券交易所停止交易。公司计划向美国证券交易委员会（“SEC”）提交相关文件，以暂停其定期报告义务并终止公司活跃注册声明下的 A 类股份的注册。</p>
</div><p>“Since our founding, NeueHealth has been committed to aligning the interests of consumers, payors, and providers to create a seamless, more coordinated care experience for all,” said Mike Mikan, President and CEO of NeueHealth. “This transaction marks a significant milestone for our Company as it allows us the flexibility and resources to continue to fulfill this mission as we advance our value-driven, consumer-centric care model and drive long-term, sustainable growth into the future.”</p>
<div class="lb-trans"><p>“自成立以来，NeueHealth 一直致力于使消费者、支付方和提供者的利益保持一致，以创造一个无缝、更加协调的护理体验，” NeueHealth 的总裁兼首席执行官 Mike Mikan 表示。“这笔交易标志着我们公司的一个重要里程碑，因为它使我们能够灵活运用资源，继续实现这一使命，推动我们以价值为驱动、以消费者为中心的护理模式，并在未来实现长期、可持续的增长。”</p>
</div><p><strong>About NeueHealth</strong></p>
<div class="lb-trans"><p><strong>关于 NeueHealth</strong></p>
</div><p>NeueHealth is a value-driven healthcare company grounded in the belief that all health consumers are entitled to high-quality, coordinated care. By uniquely aligning the interests of health consumers, providers, and payors, NeueHealth helps to make healthcare accessible and affordable to all populations across the ACA Marketplace, Medicare, and Medicaid. NeueHealth delivers high-quality clinical care to over 600,000 health consumers through owned clinics and unique partnerships with over 3,000 affiliated providers. We also enable independent providers and medical groups to thrive in performance-based arrangements through a suite of technology and services scaled centrally and deployed locally. We believe our value-driven, consumer-centric care model can transform the healthcare experience and maximize value across the healthcare system. For more information, visit: www.neuehealth.com.</p>
<div class="lb-trans"><p>NeueHealth 是一家以价值为驱动的医疗保健公司，基于所有健康消费者都有权享受高质量、协调护理的信念。通过独特地使健康消费者、提供者和支付方的利益保持一致，NeueHealth 帮助所有人群在 ACA 市场、医疗保险和医疗补助中获得可及和负担得起的医疗服务。NeueHealth 通过自有诊所和与 3000 多家附属提供者的独特合作关系，为超过 600,000 名健康消费者提供高质量的临床护理。我们还通过一套集中规模化并在本地部署的技术和服务，使独立提供者和医疗集团在基于绩效的安排中蓬勃发展。我们相信，我们以价值为驱动、以消费者为中心的护理模式可以改变医疗体验，并在整个医疗系统中最大化价值。有关更多信息，请访问：www.neuehealth.com。</p>
</div><p><strong>About NEA</strong></p>
<div class="lb-trans"><p><strong>关于 NEA</strong></p>
</div><p>New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. Founded in 1977, NEA has more than $28 billion in assets under management as of June 30, 2025 and invests in technology and healthcare companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm's long track record of investing includes 284 portfolio company IPOs and more than 500 mergers and acquisitions. For more information, please visit www.nea.com.</p>
<div class="lb-trans"><p>新企业协会（New Enterprise Associates, Inc.，简称 NEA）是一家全球风险投资公司，专注于帮助企业家在多个阶段、行业和地区建立变革性企业。NEA 成立于 1977 年，截至 2025 年 6 月 30 日，管理资产超过 280 亿美元，投资于各个生命周期阶段的技术和医疗保健公司，从种子阶段到首次公开募股（IPO）。该公司的投资历史悠久，包括 284 家投资组合公司的 IPO 和超过 500 宗并购交易。有关更多信息，请访问：www.nea.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This release contains certain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements made in this release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies, and statements as to the expected timing, completion and effects of the transaction. These statements often include words such as “anticipate,” “expect,” “plan,” “believe,” “intend,” “project,” “forecast,” “estimates,” “projections,” “outlook,” “ensure,” and other similar expressions. These forward-looking statements include any statements regarding our plans, expectations and financial guidance. Such forward-looking statements are subject to various risks, uncertainties and assumptions. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Factors that might materially affect such forward-looking statements include: the failure to complete the transaction on the anticipated terms and within the anticipated timeframe, including as a result of failure to obtain required stockholder or regulatory approvals or to satisfy other closing conditions; potential litigation relating to the transaction that could be instituted against NEA, the Company or their respective affiliates, directors, managers, officers or employees, and the effects of any outcomes related thereto; potential adverse reactions or changes to our business relationships or operating results resulting from the announcement, pendency or completion of the transaction; the risk that our stock price may decline significantly if the transaction is not consummated; certain restrictions during the pendency of the transaction that may impact our ability to pursue certain business opportunities or strategic transactions; costs associated with the transaction, which may be significant; the occurrence of events, changes or other circumstances that could give rise to the termination of the merger agreement, including in circumstances requiring us to pay a termination fee; our ability to continue as a going concern; our ability to comply with the terms of our credit facilities or any credit facility into which we enter in the future; our ability to receive the remaining proceeds from the sale of our Medicare Advantage business in California in a timely manner; our ability to obtain any short or long term debt or equity financing needed to operate our business; our ability to quickly and efficiently complete the wind down of our remaining Individual and Family Plan (“IFP”) and MA businesses, including by satisfying liabilities of those businesses when due and payable; potential disruptions to our business due to the transaction or due to corporate restructuring and any resulting headcount reduction; our ability to accurately estimate and effectively manage the costs relating to changes in our business offerings and models; a delay or inability to withdraw regulated capital from our subsidiaries; a lack of acceptance or slow adoption of our business model; our ability to retain existing consumers and expand consumer enrollment; our and our care partner’s abilities to obtain and accurately assess, code, and report risk adjustment factor scores; our ability to contract with care providers and arrange for the provision of quality care; our ability to obtain claims information timely and accurately; the impact of any pandemic or epidemic on our business and results of operations; the risks associated with our reliance on third-party providers to operate our business; the impact of modifications or changes to the U.S. health insurance markets; our ability to manage any growth of our business; our ability to operate, update or implement our technology platform and other information technology systems; our ability to retain key executives; our ability to successfully pursue acquisitions, integrate acquired businesses, and quickly and efficiently divest businesses as needed; the occurrence of severe weather events, catastrophic health events, natural or man-made disasters, and social and political conditions or civil unrest; our ability to prevent and contain data security incidents and the impact of data security incidents on our members, patients, employees and financial results; our ability to comply with requirements to maintain effective internal controls; our ability to adapt to mitigate risks associated with our ACO businesses, including any unanticipated market or regulatory developments; and the other factors set forth under the heading “Risk Factors” in the Company’s reports on Form 10-K, Form 10-Q, and Form 8-K (including all amendments to those reports) and our other filings with the SEC. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this release to conform these statements to actual results or changes in our expectations.</p>
<div class="lb-trans"><p>本公告包含根据 1995 年美国私人证券诉讼改革法案的定义所作出的某些 “前瞻性声明”。本公告中所作的非历史事实的声明，包括关于我们信念和期望的声明，均为前瞻性声明，应当作为此类声明进行评估。前瞻性声明包括有关可能或假定的未来运营结果的信息，包括我们商业计划和战略的描述，以及关于交易的预期时间、完成情况和影响的声明。这些声明通常包含 “预期”、“期待”、“计划”、“相信”、“打算”、“项目”、“预测”、“估计”、“展望”、“确保” 等类似表达。这些前瞻性声明包括关于我们计划、期望和财务指引的任何声明。这些前瞻性声明受到各种风险、不确定性和假设的影响。因此，可能存在或将存在重要因素，导致实际结果或结果与这些声明中所指示的显著不同。可能会实质性影响这些前瞻性声明的因素包括：未能按照预期条款和时间框架完成交易，包括因未能获得所需的股东或监管批准或满足其他成交条件而导致的；可能针对 NEA、公司或其各自的附属公司、董事、管理人员、高管或员工提起的与交易相关的潜在诉讼，以及与此相关的任何结果的影响；由于交易的公告、待决或完成而导致的我们商业关系或运营结果的潜在不利反应或变化；如果交易未能完成，我们的股价可能会显著下跌的风险；在交易待决期间的某些限制可能影响我们追求某些商业机会或战略交易的能力；与交易相关的成本，可能会很高；可能导致合并协议终止的事件、变化或其他情况的发生，包括在需要我们支付终止费用的情况下；我们作为持续经营实体的能力；我们遵守我们的信贷设施或未来进入的任何信贷设施条款的能力；我们及时获得加利福尼亚州医疗保险优势业务出售的剩余收益的能力；我们获得运营业务所需的任何短期或长期债务或股权融资的能力；我们迅速有效地完成剩余个人和家庭计划（“IFP”）和 MA 业务的清算的能力，包括在到期时满足这些业务的负债；由于交易或公司重组及任何导致的裁员而对我们业务造成的潜在干扰；我们准确估计和有效管理与我们业务产品和模式变化相关的成本的能力；从我们的子公司提取受监管资本的延迟或无法；对我们商业模式的接受度不足或缓慢采用；我们保留现有消费者和扩大消费者注册的能力；我们及我们的护理合作伙伴获取和准确评估、编码和报告风险调整因子评分的能力；我们与护理提供者签订合同并安排提供优质护理的能力；我们及时和准确地获取索赔信息的能力；任何疫情或流行病对我们业务和运营结果的影响；我们依赖第三方提供商运营业务的风险；对美国健康保险市场的修改或变化的影响；我们管理业务增长的能力；我们运营、更新或实施我们的技术平台和其他信息技术系统的能力；我们保留关键高管的能力；我们成功追求收购、整合收购的业务以及根据需要迅速有效地剥离业务的能力；严重天气事件、灾难性健康事件、自然或人为灾害以及社会和政治条件或社会动荡的发生；我们防止和控制数据安全事件的能力，以及数据安全事件对我们的成员、患者、员工和财务结果的影响；我们遵守维护有效内部控制要求的能力；我们适应以减轻与我们的 ACO 业务相关的风险的能力，包括任何意想不到的市场或监管发展；以及公司在 Form 10-K、Form 10-Q 和 Form 8-K（包括对这些报告的所有修订）及我们与 SEC 的其他文件中列出的 “风险因素” 标题下列出的其他因素。除法律要求外，我们没有义务在本公告日期后出于任何原因公开更新任何前瞻性声明，以使这些声明与实际结果或我们期望的变化相符。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEwMDE1OTI3OTByMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251001592790r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251001592790/en/</p>
<div class="lb-trans"><p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20251001592790/en/</p>
</div><p><strong>Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者联系：</strong></p>
</div><p>IR@neuehealth.com</p>
<div class="lb-trans"><p>IR@neuehealth.com</p>
</div><p><strong>Media Contact:</strong></p>
<div class="lb-trans"><p><strong>媒体联系：</strong></p>
</div><p>media@neuehealth.com</p>
<div class="lb-trans"><p>media@neuehealth.com</p>
</div><p>Source: NeueHealth, Inc.</p>
<div class="lb-trans"><p>来源：NeueHealth, Inc.</p>
</div>

NeueHealth 宣布完成私有化交易 | NEUE 股票新闻